Brief: HLS Therapeutics Releases New Data From Vascepa Study

HLS Therapeutics

19/03/2019 11:15

March 19 (Reuters) - HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS ANNOUNCES VASCEPA® (ICOSAPENT ETHYL)
SHOWED 30%
REDUCTION IN TOTAL CARDIOVASCULAR EVENTS INCLUDING RECURRENT
EVENTS IN REDUCE-IT™
    * HLS THERAPEUTICS INC - APPROXIMATELY 159 FEWER MAJOR
ADVERSE
CARDIOVASCULAR EVENTS PER 1000 PATIENTS STUDIED
    * HLS THERAPEUTICS INC - DATA SHOW RELATIVE BENEFITS OF
VASCEPA
USAGE GROW OVER TIME
    * HLS THERAPEUTICS INC - NO NEW SAFETY RELATED RESULTS FROM
REDUCE-IT WERE REPORTED WITH THE NEW DATA.
    * HLS THERAPEUTICS INC - REDUCE-IT STUDY, SHOWI THAT VASCEPA
PROVIDED STATISTICALLY SIGNIFICANT 30% RISK REDUCTION IN TOTAL
CARDIOVASCULAR EVENTS

Source text for Eikon:  ID:nCNWYZpTBa 
Further company coverage:  HLS.TO 

 (Reuters.Briefs@thomsonreuters.com)